12 May 2016 -  The European Commission has approved Idelvion for the treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency).

Idelvion can be used for all age groups (children and adults).

The approved treatment regimen includes routine prophylaxis to prevent or reduce the frequency of bleeding episodes; on-demand control; and the perioperative management of bleeding (around the time of surgery).

For more details, go to: http://www.csl.com.au/s1/cs/auhq/1187378853231/news/1252902671407/prdetail.htm